Archives

RP101 Phase II clinical results

April 6, 2020 11:17 am Published by jonas

Fas II-prövningen av RP101

April 6, 2020 11:17 am Published by jonas

April 5, 2020 3:25 pm Published by jonas

344 million people suffer from dry eyes

April 5, 2020 3:25 pm Published by jonas

344 miljoner människor lider av torra ögon

April 5, 2020 3:24 pm Published by jonas

The need is huge

April 5, 2020 3:24 pm Published by jonas

Behovet är stort

April 5, 2020 3:23 pm Published by jonas

Redwood Pharma develops new and improved therapies for DED

April 5, 2020 3:23 pm Published by jonas

Redwood Pharma utvecklar nya & bättre terapier mot DED

Stora Aktiedagen Stockholm 2018 – Redwood Pharma

March 22, 2020 11:22 pm Published by jonas

Aktiedagen Lund 30 januari 2018 – Redwood Pharma

March 22, 2020 11:22 pm Published by jonas

« Previous 1 … 22 23 24 25 26 … 50 Next »

Redwood Pharma

We develop ophthalmic drugs that address major medical needs. We focus on early-stage clinical development. Our long-term strategy is to enter into licence agreements with other drug companies who will in turn introduce products for the global market.

Redwood Pharma

Vi utvecklar ögonläkemedel för stora medicinska behov. Tonvikten ligger på tidig klinisk utveckling. Den långsiktiga strategin är att teckna licensavtal med andra läkemedelsbolag, som i sin tur kan introducera produkterna på världsmarknaden.